1. Symptoms of GERD

**Predominant** Heartburn +/- regurgitation.

If chest pain predominant, do cardiac workup.

No ➔ 2. Is it dyspepsia?

Yes ➔ Follow dyspepsia pathway

2. Is it dyspepsia?

• Epigastric discomfort/pain
• Upper abdominal bloating

Yes ➔ Refer for consultation / endoscopy

3. Alarm features (one or more)

• GI bleeding (hematemesis or melena) or anemia (if yes, complete CBC, INR, PTT as part of referral)
• Progressive dysphagia
• Odynophagia
• Persistent vomiting (not associated with cannabis use)
• Unintended weight loss (≥5-10% of body weight over 6 months)
• Abdominal mass

4. Consider need to screen for Barrett’s esophagus?

Screening for Barrett’s esophagus may be considered in **males** with chronic (>5 years) poorly GERD symptoms AND two or more risk factors:

• Age >50 years
• Caucasian
• Presence of central obesity (waist circumference >102cm/40" or waist-hip ratio >0.9)
• Current or past history of smoking
• Confirmed family history of Barrett’s esophagus or esophageal cancer

Given the substantially lower risk in females with chronic GERD, screening for Barrett’s esophagus in females is not recommended. It could be considered in individual cases as determined by the presence of multiple risk factors per above.

Yes ➔ Continue with pathway while awaiting screening

No ➔ Continue with pathway regardless of screening requirement

5. Non-pharmacological principles

• Smoking cessation
• Weight loss
• Elimination of food / drink triggers

Ineffective ➔ 6. Pharmacologic therapy

6. Pharmacologic therapy

Mild, infrequent symptoms < 2 times / week ➔ Yes ➔ H2RA or Antacids (PRN)

No ➔ Symptoms ≥ 2 times / week ➔ Yes ➔ PPI trial Once daily for 4-8 weeks

Symptoms resolve ➔ Discontinue or titrate down to lowest effective dose

Symptoms return ➔ PPI Maintenance

• Lowest effective dose
• Consider annual trial of deprescribing

Inadequate response ➔ Optimize PPI Twice daily for 4-8 weeks

Inadequate response ➔ Discontinue or titrate down to lowest effective dose

Last updated: January 2020
GERD Primer

- The reflux of gastric contents into the esophagus is a normal physiological phenomenon.
  - Reflux is deemed pathological when it causes esophageal injury or produces symptoms that are troublesome to the patient (typically heartburn and/or regurgitation) - a condition known as gastroesophageal reflux disease (GERD).
- A diagnosis of GERD can be made in patients with any of the clinical symptoms described above (without alarm features). Generally no investigations are required as part of the initial workup.
- Treatment at the primary care level is focused on lifestyle, smoking cessation, dietary modifications to avoid GERD triggers and achieve a healthy body weight, and optimal use of proton pump inhibitors (PPI), if needed.
- Screening for H. pylori is not recommended in GERD. Most patients with GERD do not have H. pylori and will have improvement or resolution of symptoms through lifestyle and dietary modifications or when treated with a PPI or H₂RA.
- Endoscopy is warranted in patients presenting with dysphagia or other alarm features and in those refractory to adequate initial and optimized PPI treatments. Esophageal pH or impedance-pH reflux monitoring studies are sometimes arranged by GI after endoscopy.
- GERD can be complicated by Barrett’s esophagus, esophageal stricture, and, rarely, esophageal cancer.

Expanded Details – Assessment and Treatment

1. Symptoms of GERD
   - A diagnosis of GERD can be made in patients with predominant symptoms of heartburn and/or regurgitation.
   - In some patients, GERD has a wider spectrum of symptoms including chest pain, dysphagia, globus sensation, odynophagia, nausea and water brash.
   - If patients with suspected GERD have chest pain as a dominant feature, cardiac causes should first be excluded. GERD treatment can be started while doing cardiac investigations.

2. Is it dyspepsia?
   - If the patient’s predominant symptom is epigastric pain and/or upper abdominal bloating, please refer to the dyspepsia pathway.

3. Alarm Features (warranting consideration of referral for consultation and/or endoscopy)
   - GI bleeding (hematemesis or melena – see primer on black stool on page 3) or anemia (if yes, complete CBC, INR, PTT as part of referral)
   - Progressive dysphagia
   - Odynophagia
   - Persistent vomiting (not associated with cannabis use)
   - Unintended weight loss (≥ 5-10% of body weight over 6 months)
   - Abdominal mass
4. Consider need to screen for Barrett’s esophagus

- **Males** with long-term (>5 years) poorly controlled GERD may be considered for a referral for screening for Barrett’s esophagus, but only if at least two risk factors are present:
  - Age >50 years
  - Caucasian
  - Presence of central obesity (waist circumference > 102cm/40” or waist-hip ratio > 0.9)
  - Current or past history of smoking
  - Confirmed family history of Barrett’s esophagus or esophageal cancer

- **Females** with chronic GERD have a substantially lower risk of esophageal cancer (when compared with males), and therefore screening for Barrett’s esophagus in females is not recommended. Screening could be considered in individual cases as determined by the presence of multiple risk factors as per above.
  - For females, central obesity = waist circumference > 88cm/35” or waist-hip ratio > 0.8).

- Before screening is performed, the overall life expectancy of the patient should be considered, and subsequent implications, such as the need for periodic endoscopic surveillance and therapy, if BE with dysplasia is diagnosed, should be discussed with the patient.

5. Non-pharmacological principles of GERD management (see patient resources for more information)

- **Smoking cessation is essential.**
- **Weight loss in patients who are overweight or who have recently gained weight (even if at a normal BMI).**
- Elimination of GERD triggers including alcohol, caffeine, carbonated beverages, chocolate, mint, and spicy/fatty/acidic foods, is reasonable but is not supported by clear evidence of physiological or clinical improvement of GERD.
- **Avoid meals three hours before bedtime for patients with nocturnal GERD.**
- **Consider elevating the head of bed 4-6 inches, using blocks or foam wedges. An extra pillow for sleeping is not sufficient.**
6. Pharmacologic therapy

- If symptoms are mild and infrequent (<2 times per week), histamine H₂-receptor agonists or antacids (Ca/Mg/Al salts) are recommended. These provide rapid on-demand relief of heartburn and avoid prematurely committing some patients to long-term use of PPI.
- If symptoms are ≥ 2 times per week, a trial of PPI is recommended.
- Initial PPI therapy should be once daily, 30 minutes before breakfast on an empty stomach.
  - If there is inadequate response after 4-8 weeks, step up to BID dosing for another 4-8 weeks.
  - If symptoms are controlled, it is advisable for most patients to titrate the PPI down to the lowest effective dose, and attempt once yearly to taper or stop PPI use. NOTE: patients with Barrett’s esophagus require lifetime daily PPI, regardless of whether symptoms continue.
- PPI deprescribing resources are available on the Digestive Health Strategic Clinical Network (DHSCN) website (poster, guideline, co-decision making tool for patients and health care providers).
- There are no major differences in efficacy between PPIs.

<table>
<thead>
<tr>
<th>PPI</th>
<th>Dosage</th>
<th>Estimated 90 day cost (2018)1</th>
<th>Coverage2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabeprazole</td>
<td>20mg</td>
<td>$25</td>
<td>Covered by Blue Cross/Non-insured health benefits</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>40mg</td>
<td>$30</td>
<td>Covered by Blue Cross/Non-insured health benefits</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>20mg</td>
<td>$55</td>
<td>Covered by Blue Cross/Non-insured health benefits</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>30mg</td>
<td>$60</td>
<td>Covered by Blue Cross/Non-insured health benefits</td>
</tr>
<tr>
<td>Dexlansoprazole</td>
<td>30mg</td>
<td>$230</td>
<td>Not covered by Blue Cross/NIHB</td>
</tr>
<tr>
<td>Esomeprazole</td>
<td>40mg</td>
<td>$230</td>
<td>Not covered by Blue Cross/NIHB</td>
</tr>
</tbody>
</table>

- It is estimated that 1/3 of patients with GERD will not adequately respond to PPI. Factors that predict PPI failure include obesity, poor adherence to PPI treatment, and psychological factors.
  - Patient non-adherence to treatment with PPI is common. Confirm that the patient has taken the intended dose of PPI on a daily basis, 30 minutes before breakfast.
- Patients with persistent, troublesome GERD symptoms, in spite of optimized use of PPI, should be referred for diagnostic evaluation (endoscopy ± pH/impedance reflux monitoring) to discern GERD from non-GERD etiologies.

---


2 Drug plans will only pay the cost of rabeprazole 10mg for low dose PPI and will only pay the cost of pantoprazole for high dose PPI.
### Patient Resources - Information

<table>
<thead>
<tr>
<th>Description</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>General information on GERD</td>
<td><a href="https://cdhf.ca/digestive-disorders/gerd/what-is-gastroesophageal-reflux-disease-gerd/">https://cdhf.ca/digestive-disorders/gerd/what-is-gastroesophageal-reflux-disease-gerd/</a></td>
</tr>
<tr>
<td>Online learning module on weight management</td>
<td><a href="https://myhealth.alberta.ca/learning/modules/Weight-Management">https://myhealth.alberta.ca/learning/modules/Weight-Management</a></td>
</tr>
<tr>
<td>Resources on healthy eating</td>
<td><a href="https://www.albertahealthservices.ca/nutrition/Page11115.aspx">https://www.albertahealthservices.ca/nutrition/Page11115.aspx</a></td>
</tr>
</tbody>
</table>

### Patient Resources – Services Available

<table>
<thead>
<tr>
<th>Description</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Services for patients with chronic conditions, including how to achieve a</td>
<td><a href="https://www.albertahealthservices.ca/info/page13984.aspx">https://www.albertahealthservices.ca/info/page13984.aspx</a></td>
</tr>
<tr>
<td>healthy weight (Alberta Healthy Living Program - AHS)</td>
<td></td>
</tr>
<tr>
<td>Supports to quit smoking (Alberta Quits)</td>
<td><a href="https://www.albertaquits.ca/">https://www.albertaquits.ca/</a></td>
</tr>
<tr>
<td>Supports for working towards healthy lifestyle goals and weight management</td>
<td><a href="https://www.albertahealthservices.ca/info/Page15163.aspx">https://www.albertahealthservices.ca/info/Page15163.aspx</a></td>
</tr>
<tr>
<td>(Weight Management – AHS)</td>
<td></td>
</tr>
</tbody>
</table>
Physician Resources and References

Non-urgent advice is available to support family physicians.

- Gastroenterology advice is available across the province via Alberta Netcare eReferral Advice Request (responses are received within five calendar days). Visit http://www.albertanetcare.ca/documents/Getting-Started-Advice-Requests-FAQs.pdf for more information.
- In the Calgary Zone, family physicians and specialists can be connected through Specialist LINK, a real-time tele-advice line. Visit www.specialistlink.ca to request tele-advice from a gastroenterologist. Calls are returned within one hour.
- Family physicians in the Edmonton Zone can request tele-advice via ConnectMD.(1-844-633-2263)

<table>
<thead>
<tr>
<th>Physician Resources and References</th>
</tr>
</thead>
</table>

Resources for appropriate PPI prescribing. Alberta Health Services – Digestive Health Strategic Clinical Network website.
- PPI guideline [https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-ppi-guideline.pdf](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-ppi-guideline.pdf)
- PPI co-decision making tool [https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-ppi-decision-tool.pdf](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-ppi-decision-tool.pdf)

Background on Primary Care Pathways

- Digestive health primary care pathways were originally co-developed in 2015 by gastroenterologists from the Cumming School of Medicine at the University of Calgary and family physicians representing Primary Care Networks in the Calgary Zone.
- The pathways were intended to provide evidence-based guidance to support primary care providers in caring for patients with common digestive health conditions within the medical home.
- Based on the successful adoption of the primary care pathways within the Calgary Zone, and their impact on timely access to quality care, the Digestive Health Strategic Clinical Network made the decision in 2017 to lead an initiative to validate the applicability of the pathways for all of Alberta and to spread availability and foster adoption of the pathways across Alberta.

Authors and Conflict of Interest Declaration

- Prior to provincial spread of this primary care pathway, it was reviewed and revised under the auspices of the Digestive Health Strategic Clinical Network in 2018, by a multi-disciplinary team led by family physicians and
gastroenterologists. Names of participating reviewers and their conflict of interest declarations are available on request.

Pathway Review Process and Timelines

- Primary care pathways undergo scheduled review every three years, or earlier if there is a clinically significant change in knowledge or practice. The next scheduled review is April 2022, however we welcome feedback at any time. Please submit your comments to the Digestive Health Strategic Clinical Network at Digestivehealth.SCN@ahs.ca.

DISCLAIMER
This pathway represents evidence-based best practice but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients’ specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.